Graft-versus-host disease (GVHD), due to the presence of recipient-reactive T cells, limits the usefulness of bone marrow transplantation (BMT) and is a major contributor to patient mortality. To prevent GVHD, murine and human T cells were activated by antigen or mitogens and treated with a genetically engineered form of Pseudomonas exotoxin A (PE) directed against the IL-2 receptor. Treatment with the chimeric toxin eliminated alloreactive cytotoxic T lymphocytes (CTL) as determined by cytotoxicity and mixed lymphocyte culture assays. Precursor frequencies of alloreactive cytotoxic T cells and proliferative T cells were reduced up to 100-fold as shown by limiting dilution assays. Flow cytometric analyses revealed that treatment with the chimeric toxin completely eliminated CD25 + cells from the cultures. Toxin treatment had no significant effect on hematopoietic stem and progenitor cells as determined in vitro by colony-forming assays and in vivo by long-term hematopoietic recovery after 950 rad irradiation. Toxin treatment decreased GVHD in transplanted mice to less than 10% (as compared to 88% in untreated controls). Thus, it is possible to prevent lifethreatening GVHD after BMT by using a CD25 receptor-directed toxin to eliminate host-reactive T cells from bone marrow grafts. Keywords: GVHD; graft-versus-host disease; T cells; immunotoxin Although graft-versus-host disease (GVHD) due to the presence of alloreactive T cells in stem cell grafts 1-3 is not desirable, it is tolerable in bone marrow transplantation because it is also responsible in part for timely engraftment and for the graft-versus-leukemia (GVL) effect of unrelated transplants that acts to prevent malignant relapse. [2] [3] [4] [5] [6] Although GVHD can be prevented by extensive T cell depletion of the bone marrow graft, this procedure greatly increases the risk of graft rejection and the risk of malignant relapse. Previous investigators have endeavored to prevent GVHD through various means of T cell depletion. In order
to remove T cells responsible for GVHD methods such as thymidine suicide, 7 UV-B irradiation of grafts, 8 and proliferative suicide techniques (eg hydroxyurea, Ref. 9) have been investigated over the past 20 years generally without much clinical success.
More recent approaches for T cell depletion of bone marrow grafts have used monoclonal antibodies (mAb) or rosetting with sheep red blood cells. 10 These approaches however, have suffered from the problems of inconsistent depletion efficiency and increased risks of malignant relapse and graft rejection. A variation on the mAb approach has been to attempt to induce T cell tolerance via coculture of donor and recipient cells in the presence of anti-B7-CD28/CTLA-4 mAbs. 11 Although effective in vitro, it is uncertain if such tolerance will be long-lasting in vivo after transplantation. A still more sophisticated approach has been the retroviral insertion of a cytocidal gene (eg Herpes tk gene) into activated T cells during donor/recipient cell coculture. 12 However, retroviral transfection can be inefficient and requires the administration of a pro-drug (eg ganciclovir) after transplant to treat GVHD. Furthermore, two groups of investigators have utilized similar approaches to the one described here to prevent GVHD. The group of Valteau-Couanet et al 13 utilized an anti-IL-2 receptor toxin conjugate to eliminate activated T cells. However, in their studies the mAb was conjugated to the B-k chain toxin in contrast to the Pseudomonas exotoxin used in the current studies. Finally, Rencher et al 14 have utilized a coculture approach after which activated T cells were removed by FACS-sorting to remove cells expressing the T cell activation markers HLA-DR, CD69 and CD25. This approach is somewhat more time-consuming and involved than the one presented in the current study in that one must have access to specialized equipment, there is a greater chance of introducing microbial contamination after coculture (during the sorting process), and sorting of large samples (up to a liter of bone marrow) for rare events (can be less than 1 in 1000 cells) can involve hours of sorting time at frequently expensive costs (up to $100/h at many clinical centers).
The purpose of this study was to determine whether it was possible to selectively eliminate alloreactive T cells present in a bone marrow graft that were capable of attacking the transplant recipient, without adversely affecting other T cell populations. In this way, GVHD could be effectively prevented without a negative effect on lymphocytes potentially responsible for enhancing marrow engraftment and GVL activities.
Materials and methods

Human subjects
Umbilical cord blood (CB) samples were obtained from normal full-term deliveries under the auspices of the patient's caregiver (ie physician or midwife). Collections were made after delivery of the infant and ligation of the cord, prior to expulsion of the placenta. As much blood as possible was collected from the umbilical vein using heparinized 60 ml syringes. Prior to collection of umbilical cord blood by any of these methods the cord was wiped with alcohol, followed by betadine to ensure sterility of the collections. Peripheral blood was collected from healthy laboratory volunteers by sterile venipuncture. Both cord blood and peripheral blood samples were processed into mononuclear cell populations using density gradient centrifugation as described. 15 C57BL6 spleen cells and injected into irradiated (950 rad) adult B6D2 (H-2 bxd ) recipient mice. Mice were kept in microisolator cages and observed for a period of not less than 30 days for signs of GVHD (most animals were also evaluated for periods exceeding 100 days). Engraftment was assessed by FACS analysis for the presence of H-2 b blood cells. GVHD was assessed by the presence of ruffled fur, sneezing, snuffling, the inability of the animals to move about the cage, and other signs of ill health. GVHD was also measured by examination of skin and internal organs (spleen, liver, etc) for signs of foci, necrosis, and other abnormalities. All mice were obtained from Jackson Laboratories (Bar Harbor, ME, USA) and used at an age of 12-16 weeks. Only female mice were used in these studies.
Transplants and induction of GVHD
Elimination of recipient-reactive T cells
Recipient-reactive T cells were eliminated by the culture of 50-100 × 10 6 spleen and 5 × 10 6 bone marrow cells for the murine studies, and 50 × 10 6 peripheral blood or cord blood mononuclear cells for the human studies, for the indicated periods of time with mitomycin C-treated recipient cells (or H-2-matched tumor cells) in vitro in the presence of 100 ng/ml stem cell factor (SCF). At various times either an IL-2 fusion toxin (for mouse cells) or an anti-IL-2 receptor recombinant immunotoxin was added to the cultures. These fusion proteins, IL2-PE66 4E and anti-Tac(Fv)-PE38KDEL, respectively, each contained a mutant form of Pseudomonas exotoxin. 16, 17 At the end of the culture period the cells were washed, counted and used immediately for assays and/or transplantation. Specificity controls consisted of cells treated with IL-2 and/or media.
Progenitor cell assays
Progenitor cell assays (ie colony-forming assays, CFU assays) were performed according to standard procedures 18 using methylcellulose cultures. 5 × 10 4 mononuclear cells were plated in 0.9% methylcellulose containing 30% FBS, 1% BSA, 10 -6 m 2-mercaptoethanol, l-glutamine, 50 ng/ml rH-SCF, 10 ng/ml rH-GM-CSF, 10 ng/ml rH-IL-3, and 3 U/ml rH-EPO (Stem Cell Technologies, Vancouver, Canada) in quadruplicate 60-mm Petri dishes. Cultures were incubated at 37°C in a 5% CO 2 humidified incubator. On day 14, BFU-E, CFU-E, CFU-GM and CFU-GEMM colonies as well as CFU-GM clusters were scored by morphology using an inverted light microscope. An average of the quadruplicate cultures was used to calculate total numbers of progenitor cells. Results are expressed as the numbers of progenitor cells per 50 000 cells plated.
Cytotoxicity assays
Cytotoxic T lymphocytes (CTL) were generated in standard [5] [6] [7] ) tumor cell lines (murine assays), or allogeneic peripheral blood PHA blasts (human assays) were used as target cells in the cytotoxicity experiments. Percent specific lysis was calculated as described. 20 
Limiting dilution analyses (LDA)
LDA were set up using either C57BL6 spleen cells or human peripheral blood mononuclear cells to calculate the frequencies of responding cytotoxic or helper (proliferative) T cells to a particular stimulus. 21 Briefly, various dilutions of murine or human responder cells (1 × ) were plated in 96-well microtiter plates in replicates of 24 wells for each stimulus. Stimuli consisted of either mitomycin C-treated allogeneic peripheral blood mononuclear cells or the mitogen, PHA, in the absence of IL-2 for determination of human cytotoxic T cell precursors (CTLp); or the mitogen, concanavalin A, in the presence or absence of IL-2 for the determination of murine CTLp. Either mitomycin C-treated allogeneic peripheral blood mononuclear cells, PHA, or concanavalin A in the presence or absence of IL-2 were used for determination of murine and human proliferative T lymphocyte precursors (PTLp). To determine PTLp frequencies the plates were incubated for 3 days followed by an 18 h pulse with 3 H-thymidine (1Ci/well). Thymidine incorporation (indicative of T cell stimulation and proliferation) was determined by scintillation counting. To determine CTLp frequencies the plates were incubated for a period of 7-10 days and the lytic activity of the wells tested by split well analysis 21 using a standard 51
Cr-release assay. Lectin-dependent cell-mediated cytotoxicity (LDCC) assays were performed similar to the above cytolytic assays except that 2 g/ml of PHA was added to coat the target cells to facilitate effector cell binding and lysis. 22 Data are presented as the frequency of responding cells in each of the assays for each of the stimuli rounded to the nearest thousand.
Flow cytometric analyses
One-and two-color flow cytometric (FACS) analyses were performed using a Becton Dickinson FACStar Plus flow cytometer. Cells were stained with the indicated mAbs according to standard procedures. 23 Cells alone and cells reacted with conjugated isotype control, irrelevant mAbs were used as controls. Data are presented as the percentage of cells staining positive for each individual mAb. The following mAbs were utilized: anti-CD3 (anti-pan T cells); anti-CD8 (anti-cytotoxic T cells); anti-CD4 (anti-helper T cells), anti-CD25 (anti-IL 2 receptor); anti-CD16 (anti-NK cells); and anti-CD34 (anti-stem/progenitor cells). All mAbs were obtained from Becton Dickinson (Mountain View, CA, USA) and were used according to the manufacturer's directions.
Recombinant toxins
Two toxic proteins were used in these studies. IL2-PE66 4E is a recombinant protein in which human IL-2 is fused to a mutant form of Pseudomonas exotoxin A. 16 Anti-Tac(Fv)-PE38KDEL is a recombinant protein in which the binding domain of Pseudomonas exotoxin A (amino acids 1-252) is deleted and replaced by the Fv fragment of the anti-Tac antibody that reacts with the alpha subunit of the human IL-2 receptor. 17 In addition, the carboxyterminus contains a KDEL sequence to enhance cytotoxic activity. Both proteins were produced in E. coli and purified to near homogeneity as previously described. 16, 17 The IL-2 toxin was used at a concentration of 20 ng/ml/10 6 cells, while the anti-Tac toxin was used at a concentration of 10 ng/ml/10 6 cells. Specificity controls consisted of treatment with IL-2 alone.
Results
Elimination of alloreactive, donor-specific T cells by addition of an IL-2 or anti-IL-2 receptor toxin
The feasibility of alloreactive T cell elimination was assessed by determining if such effector cells could be eliminated from standard one-way mixed lymphocyte cultures. Both murine and human effector cell cultures were established using mitomycin C-treated allogeneic stimulator cells (either allogeneic spleen cells or tumor cells for the murine cultures, and allogeneic peripheral blood cells for the human cultures). As shown in Table 1 , addition of the chimeric toxins, either the IL-2-PE66 4E toxin for the murine cultures or the anti-Tac(Fv)-PE38KDEL toxin conjugate for the human cultures, at day 2 of stimulation effectively eliminated the development of alloreactive cytolytic effector cells (up to 100% inhibition as shown by LU 20 [0]* EL4 10: ) and human peripheral blood cells from two different donors stimulated with allogeneic peripheral blood cells (PBL1 or 2-antiallogeneic PBL). On day 2 of culture the toxin (20 ng/ml/10 6 cells of IL 2-PE66 4E , or 10 ng/ml/10 6 cells of anti-Tac(Fv)-PE38KDEL) was added for the remainder of the culture period (either IL 2-toxin for the murine cells or anti-IL 2 receptor-toxin for the human cells). At the end of the culture period the cells were harvested, washed and used in 4 h cytotoxicity assays against the indicated target cells. All effector:target cell ratios (E:T) were set up based on viable cell numbers in replicates of three. Data are presented as the percent specific lysis obtained in each of the assays, and are shown as the mean ± s.d. for the individual E:T ratios. Percent specific lysis data were converted to lytic units calculated at the 20% specific lysis level and t-test statistical analyses were performed as described. 22 *indicates significant differences at the P Ͻ 0.05 level. Four independent experiments are shown. calculations). Day 2 of culture was chosen for recombinant toxin addition in order to allow for expression of IL-2 receptors after initial stimulation. The respective fusion toxins were equally effective in the murine and human effector cell cultures in eliminating cytolytic cells. Furthermore, it did not appear that there was any difference between stimulation with allogeneic stimulator cells obtained from normal donors or stimulation with allogeneic tumor cell lines. In experiments not shown, it was observed that toxin could be added as late as day 3 or as early as day 0 of effector cell culture (although in the latter circumstance a higher concentration of toxin was required) with equal effectiveness. That is, one could add the toxin at the beginning of the culture period or wait until 3 days post-initiation of the culture and achieve comparable results at day 5. Specificity of the CTL cultures was shown by the lack of CTL reactivity against H-2 b tumor cells in the murine experiments. From the above experiments it appeared that some residual cytolytic activity remained in the effector cell cultures (see higher effector cell:target cell ratios) after recom-binant toxin addition. To more definitively assess the effects of toxin conjugate on alloreactive cytolytic effector cell development, limiting dilution assays were performed to enumerate numbers of residual cytolytic T lymphocyte precursor cells (CTLp) after toxin addition (Table 2 ). After 7-10 days of culture in the presence or absence of the antiTac(Fv)-38KDEL toxin, the cultures were assessed for cytolytic activity against PHA blasts from the original blood donor or were tested for lytic activity in a LDCC assay using HLA-negative target cells (which allows for determination of total cytolytic capacity of an effector cell population independent of antigen recognition). It was observed that addition of the fusion toxin to the LDA cultures reduced the numbers of CTLp by 10-to 100-fold, regardless of how cytolytic activity was measured. As might be expected, effector cell stimulation with the mitogen PHA followed by anti-Tac(Fv)-38KDEL toxin addition was more effective in reducing numbers of CTLp than stimulation with alloantigen.
As GVHD has been demonstrated to be effectively mediated by helper and cytolytic T cells, [24] [25] [26] experiments were performed to assess the effects of toxin addition on the development of alloreactive helper T cell precursors. Helper T cell development was assessed in limiting dilution cultures by measuring the numbers of proliferative T cell precursors (PTLp) in the absence of exogenous IL-2 addition. This methodology has been previously shown to reflect helper T cells capable of secreting IL-2 in such cultures. 27 Cultures were stimulated with mitogen or alloantigen for comparison. In one experiment, exogenous IL-2 was added to the cultures to examine the effects of toxin addition on maximal T cell proliferation. As shown in Table 3, IL2-PE66 4E toxin addition reduced the numbers of PTLp by 10 to 100-fold, similar to the observation with CTLp. Once again, T cells were more effectively eliminated after stimulation with mitogen than with alloantigen. Limiting dilution assays were set up as described in the Methods. Human peripheral blood cells from three independent donors were stimulated with either allogeneic peripheral blood cells (AlloAg) or the mitogen PHA in the presence of 30 U/ml IL-2. The anti-IL-2 receptor-toxin was added on the first day of culture. After 7-10 days of stimulation the cultures were tested for cytolytic activity against either PHA blasts from the original stimulating peripheral blood donor or in a lectin-mediated assay against the HLA-negative tumor cell, K562. The frequency of cytolytic cells was calculated based on the Poisson distribution of the number of nonresponding cultures. 21 Data are presented as 1/frequency of cytolytic cells rounded to the nearest thousand. Statistical analysis was performed by 2 with * representing significant differences at the P Ͻ 0.05 level. Three independent experiments are shown.
Table 3
Reduction in PTLp frequency by toxin addition.
Cells Stimuli 1/Frequency
No toxin With toxin B6-SC Con A 15 000 1 000 000* Con A + IL-2 11 000 900 000* PBL PHA 13 000 500 000* AlloAg 70 000 1 000 000* Limiting dilution assays were set up as described in the Methods. Murine C57BL6 spleen cells (B6-SC) were stimulated with the mitogen concanavalin A (con A) in the presence or absence of exogenous IL-2 (30 U/ml).
Human peripheral blood cells (PBL) were stimulated with either allogeneic peripheral blood cells in the absence of exogenous IL-2 (AlloAg) or with the mitogen PHA in the presence of exogenous IL-2 (30 U/ml). The IL-2-toxin (murine studies) or the anti-IL 2 receptor-toxin (human studies) was added on the first day of culture. After 3 days of stimulation the cultures were pulsed for 18 h with 1 Ci/well of 3 H-thymidine and assayed for proliferation. The frequency of proliferating cells was calculated based on the Poisson distribution of the number of non-responding cultures. 21 Data are presented as 1/frequency of proliferating cells, and have been rounded to the nearest whole thousand. Statistical analysis was performed by 2 with * representing significant differences at the P Ͻ 0.05 level. Two independent experiments are shown.
These experiments demonstrated that toxin addition significantly eliminated alloreactive PTLp.
Recombinant anti-IL-2 receptor toxin addition does not affect effector or progenitor cell phenotype
In preliminary experiments, toxin addition for 5 days did not significantly alter total or viable cell numbers recovered from either murine or human cultures. Five day cultures of either human PBL (with exogenous IL-2) or murine C57BL6 spleen cells (with B6D2 spleen cells) with the toxin proteins did not result in any significant alterations of total CD4 + , CD8 + or CD16 + cells (Table 4) . However, 
Effector cell cultures were established using either human peripheral blood cells stimulated with 100 U/ml IL-2 for 5 days (PBL); human cord blood mononuclear cells stimulated with 100 U/ml IL-2 for 5 days (CB); or murine C57BL6 spleen cells stimulated with B6D2 spleen cells + 30 U/ml IL-2 for 5-7 days (B6ȰB6D2). The toxic proteins (IL 2-PE66 4E for murine studies and anti-IL-2 receptor toxin for human studies) were added at day 2 of culture. At the end of the stimulation period the cultures were harvested, washed and analyzed by flow cytometry. The coefficient of variance for the analyses was less than 10%. Data are presented as the percent of cells staining positive for each of the indicated mAbs. Statistical analyses were performed by t-tests and * represents a significant difference at the P Ͻ 0.05 level. Four independent experiments are shown. (10) 18 (7) 68 (22) 10 (5) 9 (4) 5 + 36 (12) 16 (5) 118 (12) 5 (4) 4 (3) Effector cell cultures were established using cord blood mononuclear cells (CB) stimulated for 5 days with 100 U/ml IL-2. The anti-Tac(Fv)-PE38KDEL toxin was added on day 2 of stimulation. Colony-forming assays (CFU) were set up as described in the Methods in methylcellulose assays using uncultured and untreated cells (day 0) or cells obtained at the end of the stimulation period (day 5). Colonies and clusters were scored by morphology. Data are presented as the number of colonies or clusters per 50 000 cells plated. Data are presented as the mean ±s.d. for four replicate cultures. *indicates significant differences from controls at the P Ͻ 0.05 level as determined by t-test. Two independent experiments are shown.
there was a significant reduction in cells expressing the IL-2 receptor (CD25 + cells). Cord blood mononuclear cells were also cultured with IL-2 for 5 days to examine the effect of toxin addition on stem/progenitor cells (as cord blood contains a high percentage of these cells 18 ). Toxin addition had no significant effect on the numbers or percentages of CD34 + cells. Thus, effector cell culture for 5 days in the presence of the toxin proteins does not eliminate a sufficient number of T cells to produce a significant alteration in any of the effector cell populations, or in the progenitor/stem cell population (although essentially all CD25 + cells are eliminated).
Short-term culture with stimulator cells and toxin does not affect progenitor cell numbers
Colony-forming unit (CFU) assays were performed using cord blood mononuclear cells in the presence or absence of the toxin. Only cord blood cells were utilized for these assays as cord blood contains a higher number of CFU than other sources of hematopoietic cells. 18 Culture of cord blood for 5 days with the anti-Tac(Fv)-PE38KDEL toxin in the presence of IL-2 prior to the CFU assays did not significantly effect any of the types of colonies in these assays, other than the erythroid colonies in one experiment (Table 5) . That is, addition of the toxin protein did not significantly alter the numbers of CFU-GM, CFU-GEMM or GM-clusters as compared to cells cultured without the toxin. Furthermore, preculture of cord blood cells for 5 days did not have a biologically significant effect on the CFU assays as compared to fresh, uncultured cord blood cells. Most importantly, cell culture and anti-Tac(Fv)-PE38K-DEL toxin addition had no significant effect on the number of CFU-GEMM, which are thought to correlate with the numbers of actual multipotential hematopoietic stem cells. 28 
Graft culture with recipient cells and IL-2 toxin reduces GVHD incidence and severity after transplant
The above results indicated that the toxins were effective at reducing and/or eliminating alloreactive T cells. Spleen and bone marrow cells from C57BL6 mice were cultured with spleen cells from B6D2 mice in the presence of IL2-PE66 4E for 5 days. After the culture period the cells were harvested, washed and transplanted into irradiated (950 rad) B6D2 mice. Transplanted animals were observed for у30 days for GVHD. Culture of the bone marrow graft had no effect on engraftment regardless of whether the toxin conjugate had been added, as 100% of the mice in both experimental groups engrafted. Chimerism was determined by FACS analyses performed in experiment 2, shown in Table 6 , which revealed the presence of H-2 b (+), H-2 d (−) T cells in transplanted mice. Mice that did not develop GVHD survived for longer than 100 days prior to being sacrificed for analysis. The majority of animals transplanted with untreated graft cells suffered severe GVHD (21 of 24 mice, Table 6 ). Only two of 32 mice transplanted with IL2-PE66 4E toxin-treated graft cells had significant GVHD, albeit to a lesser extent than mice receiving untreated cells. Analyses of spleens from these two groups of mice revealed that mice receiving untreated cells had a massive infiltration of CD8 + T cells (68% of splenic mononuclear cells) Bone marrow cultures were established using 50-100 × 10 6 C57BL6 spleen cells and 5 × 10 6 C57BL6 bone marrow cells stimulated with 50-100 × 10 6 B6D2 spleen cells in the presence of 30 U/ml exogenous IL-2 for 5 days. The IL2-PE66 4E toxin was added on day 2 of stimulation. At the end of the stimulation period the cultures were harvested, washed and used for transplantation into irradiated (950 rad) B6D2 mice as described in the Methods. Mice were observed for a period of not less than 30 days for signs of GVHD. Data are presented as the number of transplanted mice displaying signs of severe GVHD. In the second set of experiments spleens from transplanted mice showing severe GVHD were analyzed by flow cytometry for CD8 + cell infiltration, and the data are presented as the mean percentage of CD8 + cells found in the spleens of these animals. Three independent experiments are shown. whereas the one mouse receiving treated cells that displayed GVHD had a significantly smaller CD8 + T cell infiltrate (20% of splenic mononuclear cells). Thus, stimulation of the bone marrow graft with recipient cells in vitro with the toxin prevented GVHD and reduced the severity of GVHD in those few animals that did develop the disease.
Discussion
The frequent occurrence of severe (grades II-IV) GHVD in patients receiving matched, unrelated bone marrow transplants (MUD BMT) significantly limits its usefulness (and application) to only those diseases that cannot be managed or treated long term in another fashion. It is estimated that grade II GVHD may occur in up to 90% of MUD BMT, and that grades III-IV GVHD probably occur in up to 50% of these cases (and is estimated to occur in up to 20% of matched, sibling BMT). Thus, this treatment modality is not commonly used for diseases such as childhood leukemia in first complete remission or autoimmune diseases (eg rheumatoid arthritis) that may benefit from early intervention. Not only does severe GVHD impact on the transplant recipient's quality of life, as well as contribute significantly to the cost of therapy, but it is a major contributor to patient survival, either directly or indirectly (eg opportunistic infections due to long-term immunosuppressive therapy). If the occurrence and/or severity of GVHD could be prevented or reduced, BMT might possibly find a wider range of application.
GVHD is due to alloreactive T cells present in the bone marrow graft that recognize antigenic differences in the recipient, become activated and undergo clonal expansion. After expansion the T cells mediate their effects by direct cytolytic destruction of host tissues (eg via the actions of cytolytic T cells) or indirectly via the release of cytokines (eg TNF-␣, IL-1, IFN-␥) that are directly cytotoxic or activate other immune mechanisms. [29] [30] [31] [32] It has been postulated that although GVHD is not desirable, it is tolerable because it is also responsible in part for timely engraftment and for the graft-versus-leukemia (GVL) effect of unrelated transplants that acts to prevent malignant relapse. 5, 6 Although GVHD can be prevented by extensive T cell depletion of the bone marrow graft, this procedure increases the risk of graft rejection and the risk of malignant relapse. Recent laboratory and clinical reports 5, 6 however, have indicated that GVHD and GVL activities may lie in separate and independent T effector cell populations. Thus, it may be possible to prevent GVHD without losing the benefits of T cell-mediated engraftment and GVL.
We undertook the current study to determine if only the T cells responsible for GVHD could be eliminated from a bone marrow graft. We utilized a murine BMT model in which acute GVHD is mediated by alloreactive T cells that recognize major histocompatibiity complex antigen differences between the bone marrow donor and the transplant recipient. The model utilized donors and recipients of the same sex to eliminate gender-based variables, irradiated animals to simulate clinical conditions, and parental bone marrow transplants into F1 recipients to eliminate graft rejection possibilities (ie H-2 b into H-2 bxd , GVHD due to recognition of H-2 d antigens). Bone marrow was mixed with spleen cells from the donors to increase the numbers of alloreactive T cells in the graft, as murine bone marrow does not contain sufficient numbers of T cells to mediate acute GVHD. The goal of the study was to determine if it was possible to eliminate or reduce the numbers of alloreactive T cells in the graft, without affecting other T cell populations, and thus prevent severe GVHD without compromising engraftment. The methodology utilized was shortterm culture in vitro of the bone marrow grafts with stimulator cells from the transplant recipients in order to activate alloreactive T cells. Activated T cells express receptors for IL-2 (CD25) which upon binding of this cytokine stimulate T cell expansion. By adding a toxic protein to these cultures that reacted selectively with CD25 + T cells, after IL-2 receptor expression but prior to T cell expansion, it should be possible to eliminate these activated T cells without affecting the majority of other T cells present in the graft (as alloreactive T cells are present at a frequency of less than one in 1000). 21, 33, 34 This treatment should prevent or reduce the severity of GVHD after transplant. Two such toxic proteins were utilized in this study. For the murine studies, the IL2-PE66 4E toxin was used. 16 In the human studies, a recombinant immunotoxin in which the Fv fragment of the anti-Tac antibody is fused to Pseudomonas exotoxin (anti-Tac(Fv)-PE38KDEL) was used. 16, 17 Addition of the toxic proteins on day 2 of the MLC significantly reduced or eliminated the presence of alloreactive cytotoxic T cells directed against the stimulating allogeneic MHC antigens (by up to 100%). Importantly, the toxic proteins were effective even in the presence of exogenously added IL-2. This finding was important in that the addition of exogenous IL-2 maximizes T cell stimulation and the development of alloreactive CTL. Limiting dilution analyses demonstrated that the toxic proteins reduced the numbers of alloreactive CTLp and PTLp by 10-to 100-fold. That is, the toxins reduced both helper and cytotoxic alloreactive T cells, both of which have been demonstrated to mediate GVHD. [1] [2] [3] [4] [5] [6] [24] [25] [26] [35] [36] [37] Interestingly, toxin addition had no effect on the vast majority of T cells present in the MLC as shown by the FACS analyses. This result was not unexpected in that the frequency of alloreactive T cells is less than one cell in 1000 cells in an unprimed population of T cells. 21, 33, 34 The above experiments demonstrated that it was possible to eliminate alloreactive T cells even under strong allogeneic stimulation conditions.
To determine if these protocols would be applicable to bone marrow transplant conditions the toxin was added to stem/progenitor cell cultures and in vitro CFU assays performed. Toxin addition did not significantly affect the numbers of CFU-GM, GM-colonies or CFU-GEMM observed. In one of the experiments erythroid colonies were increased due to toxin addition, but the effect was not reproducible. These results indicated that toxin addition did not have a significant effect on either the mature or the immature hematopoietic stem/progenitor cells. Importantly, short-term culture of the hematopoietic stem/progenitor cells also had no effect on the CFU assays. These in vitro results were confirmed by the observation that irradiated animals transplanted with cultured and toxin-treated cells engrafted and survived long term (minimum of 30 days and invariably longer than 100 days).
Most noteworthy, transplantation of the cultured and treated bone marrow graft prevented the occurrence of acute GVHD in almost 100% of the transplant recipients. Animals receiving untreated (albeit cultured) bone marrow grafts invariably developed severe acute GVHD, and most either succumbed to the disease or had to be euthanized. Two animals (of 32) in the toxin-treated group that developed GVHD exhibited significantly milder cases of GVHD that were not immediately life-threatening. Analysis of the spleens of untreated animals that developed GVHD revealed a large CD8 + T cell infiltrate in these organs. Analysis of treated animals developing GVHD revealed a less smaller T cell infiltrate in the spleen, confirming the less significant nature of the disease in these animals. Thus, these experiments demonstrated that it was possible to reduce or eliminate alloreactive T cells capable of causing acute GVHD without impairing the engraftment potential of the hematopoietic stem cell graft and without compromising long-term recipient survival. It must be remembered that treated animals that survived 30 days without signs of severe GVHD invariably survived more than 100 days posttransplant, another indication that long-term reconstituting potential of the grafts had not been significantly altered.
Previously reported work with the Pseudomonas exotoxin has demonstrated it to be one of the most efficient and specific means by which to eliminate alloreactive T cells. 38 The referenced study also demonstrated that it was possible to eliminate alloreactive T cells from human MLC, although no transplants were reported. The current study confirms and extends the previous work, as well as demonstrating the feasibility of the approach to clinical bone marrow transplants. In conclusion, these experiments have demonstrated that it is possible to selectively eliminate or reduce the numbers of alloreactive T cells present in a bone marrow graft which results in prevention of or a reduction in the severity of GVHD after transplant, but does not compromise engraftment, hematopoietic rescue or recipient survival. The methodology described is simple and does not involve significant lengths of time or specialized equipment. Thus, it should be possible to transfer these findings to the clinical situation, particularly to disease conditions in which it would not be the therapy of choice but could have significant impact on long-term patient outcome.
